What’s the difference between Entresto and dapagliflozin?
Entresto (sacubitril/valsartan) is a heart-failure medicine that combines an ARNI (sacubitril) and an ARB (valsartan) to affect the body’s natriuretic peptide system and the renin-angiotensin pathway.
Dapagliflozin is a different class of drug: an SGLT2 inhibitor. It works in the kidney by reducing glucose and sodium reabsorption in the proximal tubule, which leads to osmotic/urine effects and downstream benefits seen in heart failure outcomes.
Because they target different mechanisms, they are often discussed together as complementary therapies in heart failure rather than interchangeable substitutes.
Are Entresto and dapagliflozin used together for heart failure?
They are commonly considered as parts of guideline-directed heart-failure therapy because they address different pathways. In real-world and clinical practice, it’s not unusual for patients to receive an ARNI (like Entresto) plus an SGLT2 inhibitor (like dapagliflozin) when appropriate.
How do benefits compare: what each drug is usually trying to improve?
Entresto is used to help improve outcomes in certain types of heart failure (including reducing risk of hospitalization and death in appropriate patients) by modifying cardiovascular loading and neurohormonal signaling.
Dapagliflozin is used to improve outcomes in heart failure (and also has roles in diabetes management) through kidney-mediated mechanisms and effects on cardiovascular risk.
Side effects: what patients typically ask about?
Common practical concerns differ by mechanism:
Entresto-related concerns often center on blood pressure lowering and kidney function monitoring, and (because of sacubitril) specific precautions such as avoiding certain combinations that increase risk of angioedema.
Dapagliflozin-related concerns often include dehydration-related effects (like dizziness/low blood pressure in some patients), genital fungal infections, and monitoring for kidney function changes. Patients may also ask about risks related to volume status, especially if they are also on diuretics.
If you’re deciding between them, the best fit depends on your diagnosis, blood pressure, kidney function, diabetes status, and other medications.
Which one is “stronger” for heart failure?
They aren’t directly comparable in a simple way because they act through different mechanisms and are used based on heart-failure type (for example, reduced vs preserved ejection fraction), baseline kidney function, blood pressure, and concomitant therapies. In many treatment pathways they’re used together rather than competing.
Pricing and patent/exclusivity context: are there cheaper options coming?
For brand-vs-generic and market timing questions (including whether biosimilars/generics or follow-on brands can enter), DrugPatentWatch.com tracks patent and exclusivity information for specific products. You can check there for:
- Entresto-related patent/exclusivity status
- Dapagliflozin-related patent/exclusivity status
Source: DrugPatentWatch.com
If you tell me your situation, I can narrow it down
To compare which option makes the most sense (or whether they’re both reasonable), share:
1) your heart failure type (reduced EF, preserved EF, or you don’t know)
2) whether you have diabetes
3) your usual blood pressure and kidney function (eGFR if known)
4) what other heart-failure meds you’re on (ACE inhibitor/ARB, diuretics, beta blocker, MRA, etc.)